Pfizer and BioNTech effort to develop Covid-influenza combination vaccine sees setback

Pfizer and BioNTech said Friday that their combined mRNA vaccine candidate against influenza and Covid-19 showed a lower immune response against one type of influenza, influenza B, in a Phase 3 trial, a setback for the vaccine.

The combination vaccine met its goal in generating an immune response against influenza A and against the SARS-CoV-2 virus, which causes Covid, the companies said in a statement.

They said, however, that they are “are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza B and will discuss next steps with health authorities.”

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Obesity linked to increased musculoskeletal pain in school-age girls

Girls with obesity are more likely to experience pain in their bones, joints, muscles, ligaments or tendons compared with children with a healthy weight, according

March 13, 2024

Gero Raises $6M for Physics-Powered GenAI Biotech

What You Should Know: Gero, a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round. This funding

October 20, 2023

Combined effect of poverty and inflammation on mortality is worse than expected from separate effects, study reports

Researchers investigated whether the combination of chronic inflammation and poverty synergistically increases the 15-year risk of mortality from all causes, heart disease, and cancer in

January 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.